Alzheimer’s disease is characterized by the presence of amyloid plaques in the brain. Soluble beta-amyloid (Abeta) oligomers are thought to underlie the cognitive deficits associated with Alzheimer’s disease. Cognition Therapeutics therapies pharmacologically compete with Abeta oligomers for critical receptor targets preventing synapse loss and improving memory and their small molecule therapeutics act through molecular targets that have not been previously implicated in Alzheimer’s disease.
Cognition Therapeutics has received a US patent that describes the discovery of several candidate drug molecules which can stop the effects of the brain protein that appears to play a major role in development of Alzheimer's disease. Disease-relevant screening technologyclosely models the pathology of neurodegenerative diseases and novel, high-quality CNS-biased chemical libraries. These platforms can predict behavioral efficacy of candidate drugs in Alzheimer's models. U.S. National Stage Application: No. 13/263,162, entitled "Inhibitors of Cognitive Decline" was filed on October 6, 2011.
CogRx CEO Hank Safferstein said, "The allowance of this patent demonstrates the strength of Cognition Therapeutics's intellectual property and high-level recognition that its technologies are both relevant and of great value to the therapy and ultimate conquering of Alzheimer's disease."